Unknown Mozart Manuscript To Be Auctioned

Mozart manuscript, 1783 (detail)

One of the most important Mozart discoveries of recent years will be auctioned in Berlin

BERLIN, GERMANY, April 10, 2021 /EINPresswire.com/ — One of the most important Mozart discoveries of recent years will be auctioned in Berlin on April 16. The autograph and manuscript dealer J.A.Stargardt is auctioning a recently discovered autograph music manuscript that has remained unknown to researchers until now. The sheet from 1783 shows on one side the complete first violin part for two orchestral dances, KV 609 No. 4 and KV 463 (448c) No. 1, and on the reverse side three drafts for the program of his famous concert of March 23, 1783, at the Burgtheater in Vienna.

The manuscript provides new insights into the genesis of the two dances, whose composition had previously been assigned to later years. Mozart's concert of March 23, 1783, took place under his own direction and participation in the presence of Emperor Joseph II; it became an artistic as well as a financial success and marked Mozart's establishment as a freelance musician. The drafts show Mozart's thoughts on the individual pieces, their order and the performers.

Since the mid-19th century, the manuscript has been in a German private collection. Now it will be auctioned on April 16 as part of J.A.Stargardt's autograph auction, with an estimated value of 140,000 euros.

Wolfgang Mecklenburg
J.A.Stargardt
+49 30-8822542
mecklenburg@stargardt.de


Source: EIN Presswire

Genius 100 Foundation Hosted First Ever Earth to Space Mind Experiment Performance by Master Mentalist Lior Suchard

Lior Suchard at G100 event, Montreal 2017

G100 Visionary Astronaut Dr. Soichi Noguchi aboard the ISS

At annual Genius 100 Foundation celebration of Einstein’s birthday in honor of welcoming Astronaut Dr. Soichi Noguchi as newest G100 Visionary

Since I was very young, I imagined myself successfully executing a special exercise, from earth to space, and it was one of the most profound things I have ever done”

— Lior Suchard, Master Mentalist

NEW YORK CITY, NEW YORK, UNITED STATES, April 9, 2021 /EINPresswire.com/ — On Sunday, March 14th, 2021, Einstein’s birthday, a historic, once-in-a-lifetime event took place when Astronaut Dr. Soichi Noguchi (JAXA, Japan Exploration Agency) was inducted by Genius 100 Foundation (G100) as a Genius 100 Visionary.

This event made history for several reasons, one of which was the participation of master mentalist, Lior Suchard who performed the first ever experiment of its kind within the Milky Way galaxy, between Earth and Space.

How did this happen? On the afternoon of March 14th, Genius 100 Foundation was connected to a live feed at the International Space Station for a private G100 Visionary induction ceremony and conversation with Dr. Noguchi. There were many special guests, including fellow G100 Visionaries and global dignitaries, who attended to extend congratulations. Then, as a special honor for Dr. Noguchi, he participated in the first ever successful intragalactic, Earth to Space, mind experiment with Lior Suchard. Suchard was patched in from Israel, with Noguchi, in orbit on the International Space Station.

“Einstein once said, “Imagination is more important than knowledge. For knowledge is limited, whereas imagination embraces the entire world, stimulating progress, giving birth to evolution,” stated Lior Suchard. “Since I was very young, I imagined myself successfully executing a special exercise, from earth to space, and it was one of the most profound things I have ever done. It really pushed me beyond any boundaries… even literally. And to have the opportunity to do this with Genius 100 and join in the inauguration of G100 Visionary Dr. Soichi Noguchi was incredibly humbling and a tremendous honor.”

Noguchi and Suchard initially met in 2017, at a Genius 100 Foundation event in Montreal. It was there that Noguchi saw Suchard perform and was amazed by his remarkable talent. A bond of mutual respect and admiration formed.

When he learned G100 was planning to honor Dr. Noguchi and induct him into the G100 Visionary community, Suchard joined the event committee and began to develop the idea for this intergalactic experiment.

“This was a truly phenomenal event to mark what is already a very special annual occasion for Genius 100 Foundation, as the organizations founding was inspired by Einstein,” states Hilarie Viener, CEO, Genius 100 Foundation US. “So many facets of this event showcased our community’s ability to make the impossible possible, we are filled with gratitude and more inspired than ever to share our strength and resources to support impactful global humanitarian and environmental initiatives.”

In addition to Suchard’s tremendous accomplishment, the event featured the first ever performance of “Planet 9", an opus G100 Visionary Maestro Marturet, of the Miami Symphony Orchestra. Marturet, in honor of Noguchi, composed the piece exclusively to be performed in Space. The opus included a special performance by G100 Visionary, electric guitarist Konstantin Batygin. Batygin is a world-renowned astronomer whom, amongst his many accomplishments, co-discovered the Planet 9.

About the Genius 100 Foundation
Genius 100, referred to as G100, was born out of the centennial celebration of Einstein’s Theory of Relativity (2016). To honor this landmark occasion, 100 of the world’s greatest minds were researched, selected, and nominated to contribute their vision of the future to the publishing of the first 3D book” Genius: 100 Visions of the Future.”

Founded in Toronto in 2017, with a global footprint, Genius 100 Foundation US (G100) is a 501c3 non-profit with an active and engaged community of exceptionally imaginative and impactful human beings.

The Genius 100 Visionaries (G100V) are comprised of an extraordinary group of 100 globally recognized, accomplished, compassionate minds.

The Genius 100 Foundation brings together Visionaries, philanthropic impact investors and its extended global community, collectively and in collaboration, to re-imagine the future – implement creative initiatives to improve our world – raise the bar on what is achievable and make the impossible – possible.

Genius 100 Foundation Mission
We leverage the knowledge and resources of the G100 community to support impactful humanitarian and environmental initiatives through collaboration and funding structure.

Genius 100 Foundation is a registered Charity in Canada and 501c3 US.

#######

Hilarie Viener
Genius 100 Foundation
+1 833-241-0087
email us here

Genius 100 Celebrates Einstein’s Birthday by Announcing Astronaut Soichi Noguchi as G100 Visionary


Source: EIN Presswire

Ron Howell Announces Retirement After 29 Years as CEO of Washington Research Foundation

Howell led the expansion of WRF into one of the state’s largest private foundations

Thanks to Ron, WRF is on very solid footing as it moves forward with a primary focus on the support of life-science-related technologies.”

— Tom Cable, WRF co-founder

SEATTLE, WA, USA, April 9, 2021 /EINPresswire.com/ — Ron Howell, CEO of Washington Research Foundation (WRF) since 1992, has announced that he will retire at the end of April. Under Howell’s leadership, WRF earned over $445 million in licensing revenue for the University of Washington (UW), provided more than $113 million in grants to nonprofit research institutions in the state, and invested over $90 million in 112 technology focused local startup companies.

Howell joined WRF in 1989 to create a licensing strategy for the patented technology Expression of Polypeptides in Yeast, an invention by UW colleagues Benjamin Hall, Ph.D., and Gustav Ammerer, Ph.D., alongside partners at biotechnology company Genentech, Inc. The technology is widely used in the manufacturing of vaccines and therapeutics, and Hall’s inventions are estimated to have improved the health of more than a billion people worldwide.

After becoming CEO, Howell led the expansion of WRF from primarily an intellectual property management organization into one of the largest private foundations in the state. He developed grant-making programs to support the most innovative research in Washington state’s institutions, and in 1994 created the Foundation’s venture investment arm, WRF Capital. WRF’s assets have grown from $13 million to $300 million under Howell’s leadership.

"I look forward to my retirement and look back with a lot of pride on what we've supported over the years," said Howell. "It's satisfying to know that we've helped the world's best researchers further their work. I love that I met so many great innovators and was able to learn about interesting science and engineering, then think creatively about its role, its value, and how we could help. It's a rush to see the excitement researchers get when they discuss their work, and to see the future we have with the students and postdocs. They are so bright, they work so hard, and they inspire me. The future is in good hands. Education changes lives, and research followed by application changes the world."

Tom Cable, who co-founded WRF in 1981 with Bill Gates Sr. and W. Hunter Simpson, described the Foundation’s evolution during Howell’s tenure.

“When we formed WRF, our goal was simple. We wanted to ensure that UW would benefit from the commercialization of intellectual property resulting from UW research. That was still the primary focus when Ron took over as CEO. Under Ron’s leadership, WRF has thrived and dramatically expanded its mission. Ron has assembled a terrific team of professionals with expertise in licensing of intellectual property, grant-making, venture investing and financial management. He has also established relationships with virtually all the major research institutions in the state. Thanks to Ron, WRF is on very solid footing as it moves forward with a primary focus on the support of life-science-related technologies,” said Cable.

Jeff Eby, CFO of WRF since 2002, will assume the role of acting CEO until a new leader is announced.

About Washington Research Foundation:

Washington Research Foundation (WRF) supports research and scholarship in Washington state, with a focus on life sciences and enabling technologies.

WRF was founded in 1981 to assist universities and other nonprofit research institutions in Washington with the commercialization and licensing of their technologies. WRF is one of the foremost technology transfer and grant-making organizations in the nation, having earned more than $445 million in licensing revenue for the University of Washington and providing over $113 million in grants to the state's research institutions to date.

WRF Capital, the Foundation’s venture investment arm, has funded 112 local startups since 1994. Returns from these investments support grant-making activities at WRF.

For additional information, please visit www.wrfseattle.org.

Dale Wadman
Communications Manager
+1 206-336-5600
email us here
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

Rally Foundation Teams Up With Oncoheroes Biosciences On Their Effort Of Bringing New Childhood Cancer Therapies

Rally Foundation, a new childhood cancer foundation investing in Oncoheroes Biosciences

BOSTON, MASSACHUSETTS, UNITED STATES, April 9, 2021 /EINPresswire.com/ — Childhood cancer is considered a rare disease affecting 300,000 new families every year worldwide, 90,000 of them unfortunately will lose their loved one. Moreover, more than 95% of childhood cancer survivors will have health-related issues because of the cancer treatments administered, the vast majority designed and developed for adult indications. Despite this, only five pediatric cancer drugs have been approved in the last 40 years versus more than 200 for adults, pointing to a large unmet medical need.

Oncoheroes Biosciences, currently building a multi-asset portfolio of pediatric oncology drugs, is very excited to announce the investment of Rally Foundation for Childhood Cancer Research, a pediatric cancer non-profit focused on raising awareness and funds for childhood cancer research to find better treatments with fewer long-term side effects and, ultimately, cures.

“Everything started at a lovely dinner in DC back in 2015, where four of us who led non-profit childhood cancer foundations were sharing our frustration of not seeing enough efforts from the industry on developing new therapies for children. I still remember Ricardo Garcia, who later became co-founder and CEO of Oncoheroes, proposing to launch a biotech company 100% focused on childhood cancer. We are thrilled to team up with Oncoheroes and support the effort of bringing new life-saving therapies for children and adolescents with cancer,” stated Dean Crowe co-founder and CEO of Rally Foundation.

Rally Foundation funds the most promising and cutting-edge research initiatives around the globe, seeing themselves as philanthropic seed investors in the next great discovery. Since 2005, Rally has awarded more than $22 million in childhood cancer research grants to 404 projects at hospitals and research institutions around the world and secured $31 million in new federal funding for cancers in children, adolescents, and young adults from the Department of Defense’s Medical Research Program. For the first time, Rally Foundation is investing in a biotech company.

“During that dinner in DC, I advocated for a different approach to change the pediatric cancer landscape. Today, I am very excited about this new partnership with Rally Foundation, one of the organizations involved in the conversation that took place that night. We are honored that for the first time, Rally Foundation has decided to go beyond funding academic research by investing in Oncoheroes. We believe focused disease foundations and patients’ associations play an essential role during the development of new drugs for rare diseases. Thank you Rally for joining the effort,” stated Ricardo Garcia, CEO of Oncoheroes Biosciences.

Berta Marti Fuster
ONCOHEROES BIOSCIENCES INC.
+1 8579991378
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Occupational Toxicology and Placing Worker Safety at the Forefront to be discussed at HPAPi Conference

SMi Group Reports: Key topics such as Occupational Toxicology and Placing Worker Safety at the Forefront to be discussed at SMi’s 5th Annual HPAPi Conference

LONDON, LONDON, UNITED KINGDOM, April 9, 2021 /EINPresswire.com/ — SMi Group are delighted to announce that the 5th Annual Highly Potent Active Pharmaceutical Ingredients Conference will be taking place virtually on the 10 and 11 May 2021. The two-day programme offers peer-to-peer networking opportunities with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more who will present on the several key topics being addressed, two that are particularly pertinent are Occupational Toxicology and Placing Worker Safety at the Forefront.

Interested parties can attend the conference by registering at £499 for pharmaceutical and biotechnology firms and £999 for vendors and commercial firms at http://www.highlypotentapi.com/PR4.

Sponsored by Catalent Pharma Solutions and FPS Food and Pharma Systems, this two-day agenda will have particular focus on Occupational Toxicology and Placing Worker Safety at the Forefront. Key presentations addressing these topics include the following:

Keynote Address: HPAPI – the dose makes the poison, covering:
• What is HPAPI
• What are Health Based Exposure Limits (HBELs)
• Regulatory application of HBELs in HPAPI manufacturing
Presented by: Ester Lovsin-Barle, Head of Product Stewardship and Health, Takeda

Containment Verification Testing for Pharmaceutical Equipment Performance, covering:
• Overview of ISPE Guide – Assessing the Particulate Containment Performance of Pharmaceutical Equipment (APCPPE)
• Applying the APCPPE Guide to various pharmaceutical equipment and containment systems
• Several Case Studies
Presented by: George Petroka, Principal, Director BioPharma/EHS Services, IES Engineers

Sponsor Led: Process equipment design for HPAPI containment system integration, covering:
• Are all standard Process Equipment suitable to safe handle HPAPI?
• Process Equipment critical analysis for high containment system integration
• Case studies
• Conclusions and new challenges
Presented by: Stefano Butti, Sales Director, FPS Food And Pharma Systems

A strategy in high potent compounds EHS and quality aspects, covering:
• Permitted Daily Exposure (PDE) calculations
• Evaluation of PDE compared to older standards for GMP cleaning limits
• Guidance currently available for setting toxicological evaluations
• Considerations within OEL setting for manufacturing plants from a legal background
Presented by: Reinhold Maeck, Associate Director, Tech Transfers, Boehringer Ingelheim

Hazard identification and assessment in a HPAPI environment, covering:
• Identifying potential routes of exposure to highly potent APIs
• OH exposure risk assessment and improvement projects
• PIE – Manufacturing Effluent Management
• Translating hazard assessments into appropriate engineering controls
• Strategies for effective containment improvement
Presented by: Olindo Lazzaro, Director Global EHS, AbbVie

This is an essential conference for those wanting to hear the latest insights and updates from industry leading experts in the field.

The full agenda, speaker line-up and brochure can be viewed online at http://www.highlypotentapi.com/PR4.

Sponsored by: Catalent Pharma Solutions & FPS Food and Pharma Systems
To join the conference as a sponsor and exhibitor, please get in touch with Alia Malick, Director on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

SMi’s 5th Annual Highly Potent Active Pharmaceutical Ingredients Conference
10–11 May 2021
Virtual Conference: Online Access Only
http://www.highlypotentapi.com/PR4
#SMiHPAPi

—END—

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk.

Simi Sapal
SMi Group
+442078276000
email us here


Source: EIN Presswire

Exclusive Speaker Interview with Achim Kless, Pain Genetics Lead from Eli Lilly & Company

SMi Group Reports Achim Kless, Pain Genetics Lead from Eli Lilly & Company gives an exclusive interview ahead of SMi’s 21st Annual Pain Therapeutics Conference

LONDON, LONDON, UNITED KINGDOM, April 9, 2021 /EINPresswire.com/ — Ahead of the 21st Annual Pain Therapeutics Conference, SMi Group had the pleasure of catching up with Achim Kless, pain genetics lead, Eli Lilly and Co to find out about Achim’s work, vital topics being addressed in his presentation, thoughts on the most innovative therapy and on how the pain industry is responding to the opioid crisis and what the biggest growth area will be in 2021. The conference will convene on the 10th and 11th May 2021.

Interested parties can attend the conference at £499 for pharmaceutical and biotechnology firms and £999 for vendors and commercial firms at http://www.pain-therapeutics.co.uk/PR4.

Achim will bring with him a wealth of experience with career highlights such as, a Ph.D from the University of Rostock, designing novel drugs where 3 of them have reached clinical trial status and being Scientific Director at the department of translational science and intelligence. Finally, as pain genetics lead at Eli Lilly and Co, Achim is currently researching the fields of molecular genetics and non-coding RNA for the discovery of novel pain targets.

An excerpt of his much-anticipated interview is below, of which the full interview can be found in the ‘download centre’ on http://www.pain-therapeutics.co.uk/PR4.

The Pain Therapeutics field has advanced greatly over recent years, what key differences have you noticed in the last year regarding significant developments?
“Especially the growing applications of CRISPR/CAS and gene editing allow to quickly validate novel pain targets using human cell lines. Further novel modalities like antibody conjugates and siRNA technologies enlarge the space for formerly inaccessible pain targets. Additionally, the number of GWAS cohorts like FinnGen with pain relevant phenotypes is constantly growing and results are a great source for the identification of novel targets.”

What would you say is the biggest and the most innovative therapy that is currently driving the market?
“Gene therapies especially within the area of monogenic rare diseases will lead us to a better understanding of pain pathophysiology in specific indications that can inform selection of targets and development for broader indications like chronic pain or peripheral polyneuropathies.”

Achim Kless will be speaking and looking at the future of pain therapeutics and presenting on Exploring pain genetics in rare diseases:
• From GWAS results to novel pain targets
• Exploring rare variants in pain target discovery
• Pain phenotypes across traits
• Future of drug development for rare diseases
As Europe's leading Pain Therapeutics Conference, this is an essential event for those in the field.

The full two-day programme, speaker line-up and brochure can be viewed online at http://www.pain-therapeutics.co.uk/PR4.

Proudly sponsored by: Transpharmation and MD Biosciences

To join Pain Therapeutics Conference as a sponsor/exhibitor, please get in touch with Alia Malick, Director on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

SMi’s 21st Annual Pain Therapeutics Conference
10 – 11 May 2021
Virtual Conference: Online Access Only
http://www.pain-therapeutics.co.uk/PR4
#SMiPain

— END—

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk.

Simi Sapal
SMi Group
email us here
+44 20 7827 6000


Source: EIN Presswire

Bridger Photonics’ LiDAR Technology Selected by ExxonMobil for EPA Methane Detection

This image shows LiDAR imaging of a methane plume coming from a production site, which is an example of Bridger Photonics technology.

An example of Bridger Photonics’ Gas Mapping LiDAR technology

This application is a massive breakthrough for the oil and gas industry and for Bridger. We are thrilled to be a part of it. All the hard work and innovation from our amazing team has paid off.”

— Pete Roos, CEO

BOZEMAN, MONTANA, UNITED STATES, April 9, 2021 /EINPresswire.com/ — Today, Bridger Photonics’ Light Detection and Ranging (LiDAR) technology was selected by ExxonMobil for incorporation into the first-ever filing of an application with the U.S. Environmental Protection Agency (EPA) to use cutting-edge technology for methane emissions and other regulatory compliance.

EPA Regulations (40 CFR Part 60 Subpart OOOOa) require oil and gas producers to inspect their equipment for leaks of methane volatile organic compounds and other pollutants. The regulation prescribes that field crews must visit hundreds of thousands of U.S. production sites on foot and inspect each piece of equipment by hand in search of leaks. While this leak detection process was considered the best available at the time, it is costly and time consuming, and has increased field crews’ exposures to on-site hazards.

Bridger Photonics was selected after an extensive vetting process including field trials of emerging methane detection technologies to identify more efficient, and more effective ways to detect and quantify methane leaks.

Instead of visiting sites on foot, Bridger Photonics scans sites from aircraft using its advanced LiDAR technology, Gas Mapping LiDAR™, to sensitively and quickly detect and estimate methane emissions throughout the entire natural gas value chain (production, transmission, and distribution of natural gas). Bridger hands its clients a map that pinpoints (GPS coordinates), images, and estimates the quantity of every detectable emission in the client’s infrastructure. These data products provide actionable information for field crews to easily find and prioritize leaks.

“What used to take six months for field crews to inspect now takes a matter of days with Gas Mapping LiDAR™,” said Dr. Pete Roos, CEO and co-founder of Bridger Photonics. “Bridger precisely locates and accurately quantifies methane emissions across broad areas so operators only need to deploy field crews when a leak is detected. This is a win-win for everyone involved: Bridger enables responsible operations while saving operators the cost and hazards of unnecessary visits to 60% to 90% of their sites.”

“We look forward to the EPA process establishing this alternative as equally effective as existing regulatory requirements. Our experience shows us the technology available today can detect leaks more efficiently than the manual processes federal regulations now require,” said Bart Cahir, senior vice president of unconventional at ExxonMobil. “ExxonMobil is deploying next-generation detection technologies under real-world operating conditions as part of our overall commitment to reduce methane emissions in our operations.”

Bridger Photonics’ Gas Mapping LiDAR™ is the first technology ever included in, and ExxonMobil is the first company ever to file, an application for an Alternate Means of Emissions Limitation (AMEL) for the EPA regulation. The AMEL application aims to replace ground crew visits with Gas Mapping LiDAR™.

“This AMEL application represents a massive breakthrough for the oil and gas industry and for Bridger. We are thrilled to be a part of it. All the hard work and innovation from our amazing team has paid off,” Roos added.

Bridger Photonics’ developed Gas Mapping LiDAR™ with funding from the US Department of Energy’s advanced research arm, ARPA-E, and won an R&D 100 award in 2019 recognizing the top 100 innovations worldwide for that year.

Pete Roos
Bridger Photonics
+1 406-585-2774
info@bridgerphotonics.com
Visit us on social media:
LinkedIn


Source: EIN Presswire

Erin Moriarty, Loyola’s Dean of Undergraduate Admissions, Explains How the Pandemic Changed College Admissions

A year after the pandemic began, higher education has undergone dramatic changes. COVID-19 has changed classes and transformed admissions, said Erin Moriarty.

CHICAGO, ILLINOIS, UNITED STATES, April 8, 2021 /EINPresswire.com/ — The coronavirus has impacted the world in unimaginable ways, many of which will be felt for years to come. Millions of students’ educational goals had to be put on hold or revised. To stay in step, universities have had to alter their approach to education. Nowhere is this more evident than in the college admissions process, as explained below by Erin Moriarty, Loyola University’s Dean of Undergraduate Admissions.

One of the most prominent ways universities have responded to the pandemic has been the flexibility of admission requirements. Previously, many institutions still required either the ACT or SAT as part of the application for admission. However, due to the restrictions that COVID-19 placed on testing centers, high schools, and their students, many students faced months of canceled test dates. Because of this, applicants were unable to take the test and therefore did not have this information when applying to colleges. In addition, many high school grading policies changed during the abrupt shift to remote learning, allowing for more pass and fail grades rather than the traditional grading scales. For many students, this small change may have altered their grade point average.

College admissions offices ultimately have had to adapt, easing admission requirements to allow for flexibility and accessibility during the pandemic. Without standard qualitative measurements, other aspects of the application process, including personal essays and teacher recommendations, are becoming even more valuable. Admission offices are taking a much more detailed, holistic understanding of each student’s application during the review and admission process.

To entice new applicants, many college admissions offices have offered to waive any application fees. In the pre-pandemic world, institutions would not have to waive $50 or $100 as an incentive for students to apply. However, these days, application fees can prevent high school students from applying to any given school. And while federal student aid applications have also decreased, it’s not because students don’t need the financial support; it’s because they can’t afford higher education at all.

In light of these changes, many universities are hoping to ride out the storm of COVID-19. Some institutions have made these changes permanent, while others are adjusting criteria for the next two years. Still, admission officers aspire to innovate and utilize new technologies as part of recruitment strategies moving forward.

The implementation of virtual recruitment events from individual appointments and interviews to virtual college fairs have provided new ways to communicate with students. By connecting with students virtually, schools are engaging with students prior to a traditional campus visit. This can provide access to colleges students may have otherwise not considered due to the expense or time commitment of a school visit. Opening up more options for students during the admission process has seen an increase in applications for some institutions, especially given the absence of a required standardized test.

The pandemic had changed the admission process and requirements as institutions find ways to adapt given current circumstances. Some changes may be permanent and others temporary, but one thing is certain, colleges understand the need to help students navigate the college and admission process during these unprecedented times.

About Erin Moriarty
Erin Moriarty, Loyola University Chicago’s Associate Vice President and Dean of Undergraduate Admissions, is passionate about students. She believes strongly in Loyola’s mission – to help mold young men and women to become leaders in today’s society and to seek God in all things. Outside of work, Erin can be found participating in Pedal the Cause or biking along the shores of Lake Michigan.

Erin Moriarty
Loyola University Chicago
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Kevin Matossian, CEO of Web Cloud Infrastructure Company 'SkySilk', Examines Big Tech Companies Influences in Politics

Kevin Matossian

LOS ANGELES, CA, UNITED STATES, April 8, 2021 /EINPresswire.com/ — On Monday, in his concurring opinion, Supreme Court Justice Thomas stated he believes that Facebook, Twitter, and Google should potentially be treated as utilities. Some digital networks, according to Thomas, are "sufficiently akin" to common carriers such as telecommunications companies. He also claims that Twitter's recent suspension of the @realdonaldtrump account demonstrates that outlets, not government officials, wield all the influence.

Kevin Matossian, CEO of Cloud Infrastructure company SkySilk, is in agreement with Justice Thomas and wants to take action. "What Justice Thomas articulates in his argument feels a bit like a 'dark family secret' everyone knows about, but no one ever talks about," states Matossian. "All I can say is it’s about time. We are in desperate need of a set of rules and regulations that address what is acceptable and what is not with regards to being 'online'. And to be clear, I am generally the last one to argue for more regulation, but the state of online affairs today is intolerable, and something must be done."

The Supreme Court on Monday overturned a lower court decision that found President Trump had behaved unconstitutionally by banning people on Twitter. That argument, which the justices dismissed as moot, was based on the notion that the @realdonaldtrump account was a public forum run by the president of the United States, and therefore could not stifle private speech under the Constitution. In his opinion, Justice Thomas agrees with the ruling, but argues that Twitter's recent ban of the @realdonaldtrump account shows that platforms, not government officials on them, wield the influence.

Kevin Matossian continues, "We cannot accept an online environment where our very livelihoods can be controlled or dictated by a handful of Big Tech companies and the few powerful leaders that run them. Sadly, the problem runs much deeper than simple online-presence survival. Antitrust questions, possible freedom of speech violations, and the effects on children’s mental health – because of social platforms – are all at play. There seems to be an unnatural and amplified confluence of issues that need to be addressed. We want SkySilk, and other companies like us, to be part of the solution."

"Justice Thomas’ opinion gives me hope that something can be done about the unchecked power of Big Tech," concludes Matossian. "As I have repeatedly pointed out, the actions of SkySilk with regards to the Parler platform, both represent our commitment to the spirit of the First Amendment as well as our argument against Big Tech’s repeated overreach. Justice Thomas has, I believe, laid out the framework for an argument that can lead to healthy dialogue and ultimately a 'rule book' by which we can all navigate online operations and conduct…and not one exclusively orchestrated by elite technocrats."

Aurora DeRose
Boundless Media Inc.
+1 951-870-0099
email us here


Source: EIN Presswire

Increasing Funding In The Influenza Diagnostic Industry Accelerates Progress For Greatest Public Health Impact

Influenza Diagnostic Market Report 2021: COVID-19 Implications And Growth To 2030

Influenza Diagnostic Global Market Report 2021: COVID-19 Implications And Growth To 2030

The Business Research Company’s Influenza Diagnostic Global Market Report 2021: COVID-19 Implications And Growth To 2030

LONDON, GREATER LONDON, UK, April 8, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

The major factor driving the rapid influenza diagnostic tests market is increasing funding for research on influenza diagnostics. Addressing the public health impact of the influenza disease requires a proper understanding of the virus and its effect on individuals and populations. Therefore, it is important to accelerate the pace of scientific research progress that can have the greatest public health impact. Many public and private health organizations, researchers, health professionals, biopharmaceutical companies have maximized the spending for research funds or grants to reduce the risk of the emergence of an influenza pandemic. For instance, in 2019, the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health, has initiated the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, a new network of research centers that will work together to develop influenza vaccines. NIAID will provide up to approximately $51 million in total first-year funding for the program, which is designed to support the CIVICs program centers over seven years.

Major players in the influenza diagnostic market are F. Hoffmann-La Roche Ltd, Quidel Corporation, Abbott Laboratories, Hologic, Becton, Dickinson and Company, DiaSorin S.p.A., Luminex Corporation, Meridian Bioscience, Inc., and GenMark Diagnostics.

Read More On The Global Influenza Diagnostic Market Report:
https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-market-global-report-2020-30-covid-19-implications-and-growth

The global influenza diagnostic market is expected to grow from $1.31 billion in 2020 to $1.33 billion in 2021 at a compound annual growth rate (CAGR) of 1.5%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The influenza diagnostic market is expected to reach $1.74 billion in 2025 at a CAGR of 7%.

The influenza diagnostics market covered in this report is segmented by traditional diagnostic tests into rapid influenza diagnostic tests (RIDT), viral culture, DFA, serological assays, others. The influenza diagnostic market is also segmented by molecular diagnostic tests into reverse transcription-polymerase chain reaction (RT-PCR), isothermal nucleic acid amplification tests (INAAT), loop-mediated isothermal based amplification assays, transcription-mediated isothermal based amplification assays, other isothermal nucleic acid amplification tests, other molecular diagnostic tests and by end-user into hospitals & clinical laboratories, diagnostic reference laboratories, academic/research institutes, other end-users.

Influenza Diagnostic Global Market Report 2021: COVID-19 Implications And Growth To 2030 is one of a series of new reports from The Business Research Company that provides influenza diagnostic market overview, forecast influenza diagnostic market size and growth for the whole market, influenza diagnostic market segments, and geographies, influenza diagnostic market trends, influenza diagnostic market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Influenza Diagnostic Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3237&type=smp

Here Is A List Of Similar Reports By The Business Research Company:
COVID-19 Rapid Test Kits Market- By Test Type (RT PCR Test, Rapid Antigen Test, Rapid Antibody Test, Others), By Kit Type (PCR Machines, Equipment And Extraction Kits, Reagents), By Specimen Type (Nasopharyngeal Swab, Oropharyngeal Swab, Nasal Swab, Blood, Others), By End-Users (Hospitals And Clinics, Diagnostic Laboratories, Home Care, Others), And By Region, Opportunities And Strategies – Global Forecast To 2023
https://www.thebusinessresearchcompany.com/report/covid-19-rapid-test-kits-market

Medical And Diagnostic Laboratory Services Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report-2020-30-covid-19-impact-and-recovery

Anti-Viral Drug Therapy Market – By Drug Class (DNA (Nucleotide) Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others), By Application (HIV, Hepatitis, Herpes, Influenza, Others), Anti-Viral Drug Therapy Market Size, Opportunities And Strategies – Global Anti-Viral Drug Therapy Market Forecast To 2030
https://www.thebusinessresearchcompany.com/report/anti-viral-drug-therapy-market

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire